Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non-small-cell lung cancer: 5-year follow-up of a phase II study

Publikation

Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non-small-cell lung cancer: 5-year follow-up of a phase II study

Wissenschaftlicher Artikel/Review - 24.04.2006

Betticher D C, Weder W, Stupp R, Egli F, Furrer M, Honegger H, Wernli M, Cerny Thomas, Ris H-B, Stahel R, Spiliopoulos A, Roth A D, Hsu Schmitz S-F, Tötsch M, Hansen E, Joss C, von Briel C, Schmid R A, Pless M, Habicht J, Swiss Group for Clinical Cancer Research (SAKK)

Zitation

Betticher D, Weder W, Stupp R, Egli F, Furrer M, Honegger H, Wernli M, Cerny T, Ris H, Stahel R, Spiliopoulos A, Roth A, Hsu Schmitz S, Tötsch M, Hansen E, Joss C, von Briel C, Schmid R, Pless M, Habicht J, Swiss Group for Clinical Cancer Research (SAKK). Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non-small-cell lung cancer: 5-year follow-up of a phase II study. British journal of cancer 2006; 94:1099-106.

Art

Wissenschaftlicher Artikel/Review (Englisch)

Zeitschrift

British journal of cancer 2006; 94

Veröffentlichungsdatum

24.04.2006

ISSN (Druck)

0007-0920

Seiten

1099-106

Kurzbeschreibung/Zielsetzung

The aim was to investigate the efficacy of neoadjuvant docetaxel-cisplatin and identify prognostic factors for outcome in locally advanced stage IIIA (pN2 by mediastinoscopy) non-small-cell lung cancer (NSCLC) patients. In all, 75 patients (from 90 enrolled) underwent tumour resection after three 3-week cycles of docetaxel 85 mg m-2 (day 1) plus cisplatin 40 or 50 mg m-2 (days 1 and 2). Therapy was well tolerated (overall grade 3 toxicity occurred in 48% patients; no grade 4 nonhaematological toxicity was reported), with no observed late toxicities. Median overall survival (OS) and event-free survival (EFS) times were 35 and 15 months, respectively, in the 75 patients who underwent surgery; corresponding figures for all 90 patients enrolled were 28 and 12 months. At 3 years after initiating trial therapy, 27 out of 75 patients (36%) were alive and tumour free. At 5-year follow-up, 60 and 65% of patients had local relapse and distant metastases, respectively. The most common sites of distant metastases were the lung (24%) and brain (17%). Factors associated with OS, EFS and risk of local relapse and distant metastases were complete tumour resection and chemotherapy activity (clinical response, pathologic response, mediastinal downstaging). Neoadjuvant docetaxel-cisplatin was effective and tolerable in stage IIIA pN2 NSCLC, with chemotherapy contributing significantly to outcomes.